{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:10Z","timestamp":1790052970863,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG37491-10"],"award-info":[{"award-number":["R01 AG37491-10"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P50 AG16574"],"award-info":[{"award-number":["P50 AG16574"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG006786"],"award-info":[{"award-number":["U01 AG006786"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00415-024-12312-5","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T09:01:31Z","timestamp":1712307691000},"page":"4105-4118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A multimodal clinical diagnostic approach using MRI and 18F-FDG-PET for antemortem diagnosis of TDP-43 in cases with low\u2013intermediate Alzheimer\u2019s disease neuropathologic changes and primary age-related tauopathy"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7521-7082","authenticated-orcid":false,"given":"Anna","family":"Lavrova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nha Trang Thu","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arenn F.","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Whitwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Josephs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"issue":"5","key":"12312_CR1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.24493","volume":"78","author":"KA Josephs","year":"2015","unstructured":"Josephs KA et al (2015) TAR DNA-binding protein 43 and pathological subtype of Alzheimer\u2019s disease impact clinical features. Ann Neurol 78(5):697\u2013709","journal-title":"Ann Neurol"},{"issue":"11","key":"12312_CR2","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD et al (2016) TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain 139(11):2983\u20132993","journal-title":"Brain"},{"issue":"4","key":"12312_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bpa.12424","volume":"27","author":"KE McAleese","year":"2017","unstructured":"McAleese KE et al (2017) TDP-43 pathology in Alzheimer\u2019s disease, dementia with Lewy bodies and ageing. Brain Pathol 27(4):472\u2013479","journal-title":"Brain Pathol"},{"issue":"6","key":"12312_CR4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00401-011-0879-y","volume":"122","author":"YS Davidson","year":"2011","unstructured":"Davidson YS et al (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer\u2019s disease, late onset Alzheimer\u2019s disease and down\u2019s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 122(6):703\u2013713","journal-title":"Acta Neuropathol"},{"issue":"19 Part 2","key":"12312_CR5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/01.wnl.0000304041.09418.b1","volume":"70","author":"KA Josephs","year":"2008","unstructured":"Josephs KA et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70(19 Part 2):1850\u20131857","journal-title":"Neurology"},{"issue":"3","key":"12312_CR6","first-page":"804","volume":"140","author":"PA Boyle","year":"2017","unstructured":"Boyle PA et al (2017) Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain 140(3):804\u2013812","journal-title":"Brain"},{"issue":"11","key":"12312_CR7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/jamaneurol.2013.3961","volume":"70","author":"RS Wilson","year":"2013","unstructured":"Wilson RS et al (2013) TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 70(11):1418\u20131424","journal-title":"JAMA Neurol"},{"issue":"2","key":"12312_CR8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5114\/fn.2023.128776","volume":"61","author":"A Acewicz","year":"2023","unstructured":"Acewicz A et al (2023) Incidence and morphology of secondary TDP-43 proteinopathies: part 2. Folia Neuropathol 61(2):111\u2013120","journal-title":"Folia Neuropathol"},{"issue":"6","key":"12312_CR9","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503\u20131527","journal-title":"Brain"},{"issue":"11","key":"12312_CR10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(17)30284-3","volume":"16","author":"KA Josephs","year":"2017","unstructured":"Josephs KA et al (2017) Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer\u2019s disease: a longitudinal retrospective study. Lancet Neurol 16(11):917\u2013924","journal-title":"Lancet Neurol"},{"issue":"6","key":"12312_CR11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA et al (2014) TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathol 127(6):811\u2013824","journal-title":"Acta Neuropathol"},{"issue":"3","key":"12312_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00401-013-1211-9","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA et al (2014) Staging TDP-43 pathology in Alzheimer\u2019s disease. Acta Neuropathol 127(3):441\u2013450","journal-title":"Acta Neuropathol"},{"issue":"4","key":"12312_CR13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/awy049","volume":"141","author":"H Botha","year":"2018","unstructured":"Botha H et al (2018) FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain 141(4):1201\u20131217","journal-title":"Brain"},{"key":"12312_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1843","author":"M Buciuc","year":"2022","unstructured":"Buciuc M et al (2022) Differences in rate and trajectory of TDP-43-associated neurodegeneration in brains with and without frontotemporal lobar degeneration (S20.007). Neurology. https:\/\/doi.org\/10.1212\/WNL.98.18_supplement.1843","journal-title":"Neurology"},{"issue":"4","key":"12312_CR15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3233\/JAD-191040","volume":"73","author":"M Buciuc","year":"2020","unstructured":"Buciuc M et al (2020) Effect modifiers of TDP-43-associated hippocampal atrophy rates in patients with Alzheimer\u2019s disease neuropathological changes. J Alzheimers Dis 73(4):1511\u20131523","journal-title":"J Alzheimers Dis"},{"key":"12312_CR16","doi-asserted-by":"crossref","first-page":"102954","DOI":"10.1016\/j.nicl.2022.102954","volume":"34","author":"M Buciuc","year":"2022","unstructured":"Buciuc M et al (2022) TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage Clin 34:102954","journal-title":"NeuroImage Clin"},{"issue":"11","key":"12312_CR17","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1093\/brain\/awaa299","volume":"143","author":"KA Josephs","year":"2020","unstructured":"Josephs KA et al (2020) Protein contributions to brain atrophy acceleration in Alzheimer\u2019s disease and primary age-related tauopathy. Brain 143(11):3463\u20133476","journal-title":"Brain"},{"issue":"9","key":"12312_CR18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1474-4422(18)30251-5","volume":"17","author":"H-S Yang","year":"2018","unstructured":"Yang H-S et al (2018) Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE \u03b54 haplotype status: a community-based cohort study. Lancet Neurol 17(9):773\u2013781","journal-title":"Lancet Neurol"},{"issue":"11","key":"12312_CR19","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamaneurol.2018.3139","volume":"75","author":"AM Wennberg","year":"2018","unstructured":"Wennberg AM et al (2018) Association of apolipoprotein E \u03b54 with transactive response DNA-binding protein 43. JAMA Neurol 75(11):1347\u20131354","journal-title":"JAMA Neurol"},{"issue":"5","key":"12312_CR20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/brain\/awr053","volume":"134","author":"PT Nelson","year":"2011","unstructured":"Nelson PT et al (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134(5):1506\u20131518","journal-title":"Brain"},{"issue":"2","key":"12312_CR21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00401-013-1154-1","volume":"126","author":"PT Nelson","year":"2013","unstructured":"Nelson PT et al (2013) Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol 126(2):161\u2013177","journal-title":"Acta Neuropathol"},{"issue":"1","key":"12312_CR22","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1212\/WNL.0000000000009722","volume":"95","author":"M Buciuc","year":"2020","unstructured":"Buciuc M et al (2020) Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology 95(1):e23\u2013e34","journal-title":"Neurology"},{"issue":"4","key":"12312_CR23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259","journal-title":"Acta Neuropathol"},{"issue":"4","key":"12312_CR24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389\u2013404","journal-title":"Acta Neuropathol"},{"issue":"3","key":"12312_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr et al (2017) Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement 13(3):205\u2013216","journal-title":"Alzheimers Dement"},{"issue":"3","key":"12312_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183\u2013194","journal-title":"J Intern Med"},{"issue":"7","key":"12312_CR27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archpsyc.1983.01790060110016","volume":"40","author":"MF Folstein","year":"1983","unstructured":"Folstein MF, Robins LN, Helzer JE (1983) The mini-mental state examination. Arch Gen Psychiatry 40(7):812\u2013812","journal-title":"Arch Gen Psychiatry"},{"key":"12312_CR28","unstructured":"Mattis, S (1988) Dementia rating scale: professional manual. Psychological assessment resources, Incorporated."},{"issue":"1","key":"12312_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT et al (2012) National Institute on aging\u2013Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8(1):1\u201313","journal-title":"Alzheimers Dement"},{"issue":"12","key":"12312_CR30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR et al (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791\u20131800","journal-title":"Neurology"},{"issue":"4","key":"12312_CR31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-016-1537-1","volume":"131","author":"KA Josephs","year":"2016","unstructured":"Josephs KA et al (2016) Updated TDP-43 in Alzheimer\u2019s disease staging scheme. Acta Neuropathol 131(4):571\u2013585","journal-title":"Acta Neuropathol"},{"issue":"2","key":"12312_CR32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00401-008-0400-4","volume":"116","author":"WT Hu","year":"2008","unstructured":"Hu WT et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 116(2):215","journal-title":"Acta Neuropathol"},{"issue":"5","key":"12312_CR33","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/brain\/awm065","volume":"130","author":"M Hasegawa","year":"2007","unstructured":"Hasegawa M et al (2007) TDP-43 is deposited in the Guam parkinsonism\u2013dementia complex brains. Brain 130(5):1386\u20131394","journal-title":"Brain"},{"key":"12312_CR34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00401-013-1211-9","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA et al (2014) Staging TDP-43 pathology in Alzheimer\u2019s disease. Acta Neuropathol 127:441\u2013450","journal-title":"Acta Neuropathol"},{"key":"12312_CR35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-016-1537-1","volume":"131","author":"KA Josephs","year":"2016","unstructured":"Josephs KA et al (2016) Updated TDP-43 in Alzheimer\u2019s disease staging scheme. Acta Neuropathol 131:571\u2013585","journal-title":"Acta Neuropathol"},{"issue":"6","key":"12312_CR36","first-page":"p.re1","volume":"2006","author":"DR Thal","year":"2006","unstructured":"Thal DR et al (2006) The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006(6):p.re1","journal-title":"Sci Aging Knowledge Environ"},{"issue":"2","key":"12312_CR37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal DR et al (2015) Neuropathology and biochemistry of A\u03b2 and its aggregates in Alzheimer\u2019s disease. Acta Neuropathol 129(2):167\u2013182","journal-title":"Acta Neuropathol"},{"key":"12312_CR38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755\u2013766","journal-title":"Acta Neuropathol"},{"issue":"3","key":"12312_CR39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/WAD.0b013e318142774e","volume":"21","author":"DL Beekly","year":"2007","unstructured":"Beekly DL et al (2007) The national Alzheimer\u2019s coordinating center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord 21(3):249\u2013258","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"12312_CR40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/NEN.0b013e318292492a","volume":"72","author":"T Rauramaa","year":"2013","unstructured":"Rauramaa T et al (2013) Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study. J Neuropathol Exp Neurol 72(6):452\u2013461","journal-title":"J Neuropathol Exp Neurol"},{"key":"12312_CR41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0072-9752(07)01253-5","volume":"89","author":"C Amador-Ortiz","year":"2008","unstructured":"Amador-Ortiz C, Dickson DW (2008) Neuropathology of hippocampal sclerosis. Handb Clin Neurol 89:569\u2013572","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"12312_CR42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","volume":"131","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr et al (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer\u2019s disease and amnestic mild cognitive impairment. Brain 131(3):665\u2013680","journal-title":"Brain"},{"issue":"2","key":"12312_CR43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jnnp.70.2.165","volume":"70","author":"CJ Galton","year":"2001","unstructured":"Galton CJ et al (2001) Temporal lobe rating scale: application to Alzheimer\u2019s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 70(2):165\u2013173","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"12312_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0022-510X(93)90041-V","volume":"114","author":"P Scheltens","year":"1993","unstructured":"Scheltens P et al (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114(1):7\u201312","journal-title":"J Neurol Sci"},{"issue":"2","key":"12312_CR45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F et al (1987) MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. Am J Roentgenol 149(2):351\u2013356","journal-title":"Am J Roentgenol"},{"issue":"5","key":"12312_CR46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F et al (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36(5):268\u2013272","journal-title":"Eur Neurol"},{"issue":"5","key":"12312_CR47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000100973","volume":"23","author":"CM Kipps","year":"2007","unstructured":"Kipps CM et al (2007) Clinical significance of lobar atrophy in frontotemporal dementia: application of an mri visual rating scale. Dement Geriatr Cogn Disord 23(5):334\u2013342","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"12312_CR48","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"EL Koedam","year":"2011","unstructured":"Koedam EL et al (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21(12):2618\u20132625","journal-title":"Eur Radiol"},{"issue":"7","key":"12312_CR49","first-page":"1238","volume":"36","author":"S Minoshima","year":"1995","unstructured":"Minoshima S et al (1995) A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36(7):1238\u20131248","journal-title":"J Nucl Med"},{"key":"12312_CR50","unstructured":"Team RC (2012) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. URL http:\/\/www.R-project.org, 2018."},{"key":"12312_CR51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA et al (2014) TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathol 127:811\u2013824","journal-title":"Acta Neuropathol"},{"issue":"11","key":"12312_CR52","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1093\/brain\/awz277","volume":"142","author":"A Bejanin","year":"2019","unstructured":"Bejanin A et al (2019) Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain 142(11):3621\u20133635","journal-title":"Brain"},{"issue":"4","key":"12312_CR53","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/alz.12763","volume":"19","author":"MJ Grothe","year":"2023","unstructured":"Grothe MJ et al (2023) Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC. Alzheimers Dement 19(4):1234\u20131244","journal-title":"Alzheimers Dement"},{"key":"12312_CR54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuropsychologia.2014.08.013","volume":"63","author":"KC Bickart","year":"2014","unstructured":"Bickart KC, Dickerson BC, Barrett LF (2014) The amygdala as a hub in brain networks that support social life. Neuropsychologia 63:235\u2013248","journal-title":"Neuropsychologia"},{"issue":"1","key":"12312_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90247-L","volume":"44","author":"A McDonald","year":"1991","unstructured":"McDonald A (1991) Organization of amygdaloid projections to the prefrontal cortex and associated striatum in the rat. Neuroscience 44(1):1\u201314","journal-title":"Neuroscience"},{"issue":"4","key":"12312_CR56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/scan\/nsm029","volume":"2","author":"SJ Banks","year":"2007","unstructured":"Banks SJ et al (2007) Amygdala\u2013frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci 2(4):303\u2013312","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"4","key":"12312_CR57","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neurobiolaging.2006.10.032","volume":"29","author":"KA Josephs","year":"2008","unstructured":"Josephs KA et al (2008) Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol Aging 29(4):566\u2013573","journal-title":"Neurobiol Aging"},{"issue":"1","key":"12312_CR58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/JAD-230238","volume":"96","author":"AC Leiby","year":"2023","unstructured":"Leiby AC et al (2023) Characterizing limbic-predominant age-related TDP-43 encephalopathy without Alzheimer\u2019s disease and lewy body dementia in the oldest old: a case series. J Alzheimers Dis 96(1):113\u2013124","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12312-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12312-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12312-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T06:26:34Z","timestamp":1720506394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12312-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["12312"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12312-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Lavrova, Nha Trang Thu Pham and Cynthia J. Vernon reports no conflicts of interest. Dennis W. Dickson, Jennifer L. Whitwell, and Keith A. Josephs receive research support from the NIH\/NIA\/NINDS\/NIDCD. Val J. Lowe consults for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). Ronald C. Petersen serves on data monitoring committees for Janssen Alzheimer Immunotherapy, and is a consultant for Biogen, Roche, Merck, and Genentech, Inc; receives publishing royalties from\u00a0<i>Mild Cognitive Impairment<\/i>\u00a0(Oxford University Press, 2003), and receives research support from the NIH\/NIA. C.R. Jack, Jr. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}